Programmable Poly‐Lactic‐Co‐Glycolic Acid Nanocarriers for Precision Therapy of Pancreatic Ductal Adenocarcinoma
Drug Development Research · 2026-05 · 87 (3)
DOI: 10.1002/ddr.70307 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Development Research, online erschienen am 12.05.2026. Verfasst von Shruti Gupta und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioscience and Biomedical Engineering, Indian Institute of Technology Bhilai, Kutelabhata, Durg, Chhattisgarh, India. Hauptthemen laut MEDLINE: Polylactic Acid-Polyglycolic Acid Copolymer, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Drug Carriers. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 109 Literaturangaben. Gefördert von: Deanship of Research and Graduate Studies at King Khalid University.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignancies, characterized by late‐stage diagnosis, dense desmoplastic stroma, rapid metastatic progression, and poor responsiveness to conventional chemotherapy. Consequently, the development of effective drug delivery strategies capable of overcoming stromal and resistance barriers remains an urgent clinical priority. Poly (lactic‐co‐glycolic acid) (PLGA) nanoparticles have emerged as a versatile biomaterials platform for improving therapeutic outcomes through enhanced drug solubility, sustained release, and favorable pharmacokinetics. This review critically examines recent advances in the rational design and functionalization of PLGA‐based nanocarriers for PDAC therapy, with particular emphasis on tumor‐targeted delivery, stromal modulation, and strategies to overcome multidrug resistance. Surface engineering approaches, including ligand conjugation and stimuli‐responsive systems, have shown considerable promise in enhancing intratumoral penetration and therapeutic efficacy. In addition, advanced nanoscale analytical and interfacial characterization techniques such as dynamic light scattering, electron microscopy, and zeta potential analysis provide important mechanistic insights into particle stability, cellular interactions, and drug–polymer dynamics, thereby guiding formulation optimization. Collectively, current evidence highlights the strong translational potential of PLGA nanocarriers in precision oncology for PDAC. Continued integration of biomaterials engineering with disease‐specific targeting and rigorous physicochemical characterization will be essential to accelerate clinical development and improve patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bioscience and Biomedical Engineering, Indian Institute of Technology Bhilai, Kutelabhata, Durg, Chhattisgarh, India.
- Department of Basic Medical Sciences, College of Applied Medical Sciences, Khamis Mushait, King Khalid University, Abha, Saudi Arabia.
- Department of Pharmacognosy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.
- Graphic Era Hill University, Dehradun, India.
- School of Allied Medical Sciences, Lovely Professional University, Phagwara, Punjab, India.
- Faculty of Data Science and Information Technology, INTI International University, Nilai, Malaysia.
ORCID-Profile: Khang Wen Goh, Prashant Kesharwani
Förderung
- Deanship of Research and Graduate Studies at King Khalid University
Zitieren
APA
Gupta, S., Nasir, N., Wahab, S., Gupta, G., Goh, K. W., & Kesharwani, P. (2026). Programmable Poly‐Lactic‐Co‐Glycolic Acid Nanocarriers for Precision Therapy of Pancreatic Ductal Adenocarcinoma. Drug Development Research, 87(3). https://doi.org/10.1002/ddr.70307
Vancouver
Gupta S, Nasir N, Wahab S, Gupta G, Goh KW, Kesharwani P. Programmable Poly‐Lactic‐Co‐Glycolic Acid Nanocarriers for Precision Therapy of Pancreatic Ductal Adenocarcinoma. Drug Development Research. 2026;87(3). doi:10.1002/ddr.70307
BibTeX
@article{Gupta2026,
author = {Gupta, Shruti and Nasir, Nazim and Wahab, Shadma and Gupta, Garima and Goh, Khang Wen and Kesharwani, Prashant},
title = {Programmable Poly‐Lactic‐Co‐Glycolic Acid Nanocarriers for Precision Therapy of Pancreatic Ductal Adenocarcinoma},
journal = {Drug Development Research},
year = {2026},
volume = {87},
number = {3},
doi = {10.1002/ddr.70307}
}
EUVIMED